Skip to main content
Top
Published in: Diabetes Therapy 4/2015

Open Access 01-12-2015 | Original Research

The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes

Published in: Diabetes Therapy | Issue 4/2015

Login to get access

Abstract

Introduction

The aim of this study was to examine the influence of weight change experiences over time on motivation to perform diabetes self-care behaviors using data from a study of canagliflozin (an agent that inhibits sodium glucose co-transporter 2) versus glimepiride in dual therapy with metformin and background diet/exercise.

Methods

Weight and motivation for performing healthy behaviors were collected at baseline and over time. The motivation questionnaire enabled categorization into two groups: those performing or not performing health behaviors. Four distinct patterns of weight change were determined: losing weight, gaining weight, and two patterns for fluctuating weight. The relationships between these patterns and motivation for weight loss, following a diet, and exercise were examined using logistic regression models.

Results

Of 1182 subjects, more than half were already performing behaviors to lose weight, diet, and exercise at baseline. Among those who were not, 52% (246/474) started taking action to lose weight after baseline, 54% (241/448) started following a diet, and 42% (232/556) started exercising. Weight change patterns were significantly related to performance of healthy behaviors at follow-up (week 36). Compared to the weight gain pattern, those who experienced a continuous weight loss pattern from baseline to week 36 were 2.2 (95% confidence interval 1.49, 3.37) times more likely to perform the healthy behaviors. Baseline behavior and confidence were also predictive of performing healthy behaviors.

Conclusion

The current work highlights the importance of weight change patterns for performance of diabetes self-care. Tracking weight patterns over time, assessing confidence for performance of healthy behaviors, and being aware of the relationship between weight changes and diabetes self-care behaviors are viable, concrete ways to practice patient-centered care.

Funding

Janssen Global Services, LLC.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Association of Diabetes Educators Position Statement. AADE7 self-care behaviors. Diabetes Educ. 2008;34:445–9.CrossRef American Association of Diabetes Educators Position Statement. AADE7 self-care behaviors. Diabetes Educ. 2008;34:445–9.CrossRef
2.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralCrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralCrossRefPubMed
3.
go back to reference Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215.CrossRefPubMed Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215.CrossRefPubMed
4.
go back to reference Tripp-Reimer T, Choi E, Skemp Kelley L, Enslein JC. Cultural barriers to care: inverting the problem. Diabetes Spectrum. 2001;14:13–22.CrossRef Tripp-Reimer T, Choi E, Skemp Kelley L, Enslein JC. Cultural barriers to care: inverting the problem. Diabetes Spectrum. 2001;14:13–22.CrossRef
5.
go back to reference Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self-management and quality of life. Diabetes Spectrum. 2001;14:33–41.CrossRef Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self-management and quality of life. Diabetes Spectrum. 2001;14:33–41.CrossRef
6.
go back to reference Coonrod BA. Overcoming physical barriers to diabetes self-care: reframing disability as an opportunity for ingenuity. Diabetes Spectrum. 2001;14:28–32.CrossRef Coonrod BA. Overcoming physical barriers to diabetes self-care: reframing disability as an opportunity for ingenuity. Diabetes Spectrum. 2001;14:28–32.CrossRef
7.
go back to reference Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011;93:1–9.CrossRefPubMed Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011;93:1–9.CrossRefPubMed
8.
go back to reference Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: 4-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.PubMed Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: 4-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.PubMed
9.
go back to reference Kavookjian J. Motivational interviewing. Science and practice of pharmacotherapy I and II—PSAP-VII, Book 8. Lenexa: American College of Clinical Pharmacy; 2011. p. 1–18. Kavookjian J. Motivational interviewing. Science and practice of pharmacotherapy I and II—PSAP-VII, Book 8. Lenexa: American College of Clinical Pharmacy; 2011. p. 1–18.
10.
go back to reference Miller WR, Rollnick S. Motivational interviewing: preparing people for change. New York: Guilford Press; 2002. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. New York: Guilford Press; 2002.
11.
go back to reference Song D, Xu TZ, Sun QH. Effect of motivational interviewing on self-management in patients with type 2 diabetes mellitus: a meta-analysis. Int J Nurs Sci. 2014;1:291–7. Song D, Xu TZ, Sun QH. Effect of motivational interviewing on self-management in patients with type 2 diabetes mellitus: a meta-analysis. Int J Nurs Sci. 2014;1:291–7.
12.
go back to reference Prochaska J, Norcross J. Systems of psychotherapy—a transtheoretical analysis. New York: Wadsworth Pub Co; 2003. Prochaska J, Norcross J. Systems of psychotherapy—a transtheoretical analysis. New York: Wadsworth Pub Co; 2003.
13.
go back to reference Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. Am J Prev Med. 1999;17:275–84.CrossRefPubMed Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. Am J Prev Med. 1999;17:275–84.CrossRefPubMed
14.
go back to reference Johnson SS, Paiva AL, Cummins CO, Johnson JL, Dyment SJ, Wright JA, et al. Transtheoretical model-based multiple behavior intervention for weight management: effectiveness on a population basis. Prev Med. 2008;46:238–46.PubMedCentralCrossRefPubMed Johnson SS, Paiva AL, Cummins CO, Johnson JL, Dyment SJ, Wright JA, et al. Transtheoretical model-based multiple behavior intervention for weight management: effectiveness on a population basis. Prev Med. 2008;46:238–46.PubMedCentralCrossRefPubMed
15.
go back to reference Ruggiero L. Helping people with diabetes change behavior: from theory to practice. Diabetes Spectrum. 2000;13:125–31. Ruggiero L. Helping people with diabetes change behavior: from theory to practice. Diabetes Spectrum. 2000;13:125–31.
16.
go back to reference Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.CrossRefPubMed Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.CrossRefPubMed
17.
go back to reference Jones H, Edwards L, Vallis TM, Ruggiero L, Rossi SR, Rossi JS, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the diabetes stages of change (DiSC) study. Diabetes Care. 2003;26:732–7.CrossRefPubMed Jones H, Edwards L, Vallis TM, Ruggiero L, Rossi SR, Rossi JS, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the diabetes stages of change (DiSC) study. Diabetes Care. 2003;26:732–7.CrossRefPubMed
18.
go back to reference Graffigna G, Barello S, Libreri C, Bosio CA. How to engage type-2 diabetic patients in their own health management: implications for clinical practice. BMC Public Health. 2014;14:648.PubMedCentralCrossRefPubMed Graffigna G, Barello S, Libreri C, Bosio CA. How to engage type-2 diabetic patients in their own health management: implications for clinical practice. BMC Public Health. 2014;14:648.PubMedCentralCrossRefPubMed
19.
go back to reference Blake CE, Hebert JR, Lee DC, Adams SA, Steck SE, Sui X, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371.PubMedCentralCrossRefPubMed Blake CE, Hebert JR, Lee DC, Adams SA, Steck SE, Sui X, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371.PubMedCentralCrossRefPubMed
20.
go back to reference Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15.CrossRefPubMed Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15.CrossRefPubMed
21.
go back to reference Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials. 2009;10:43.PubMedCentralCrossRefPubMed Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials. 2009;10:43.PubMedCentralCrossRefPubMed
22.
go back to reference Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.CrossRefPubMed Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.CrossRefPubMed
23.
go back to reference Leiter LA, Yoon K-H, Arias P, Langslet G, Xie J, Balis D, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care. 2015;38:355–64.CrossRefPubMed Leiter LA, Yoon K-H, Arias P, Langslet G, Xie J, Balis D, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care. 2015;38:355–64.CrossRefPubMed
24.
go back to reference Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9:102–11.CrossRefPubMed Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9:102–11.CrossRefPubMed
25.
go back to reference Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J. The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J Behav Med. 1997;20:291–312.CrossRefPubMed Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J. The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J Behav Med. 1997;20:291–312.CrossRefPubMed
26.
go back to reference Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267–73.CrossRefPubMed Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267–73.CrossRefPubMed
27.
go back to reference Bolin JH, Edwards JM, Finch WH, Cassady JC. Applications of cluster analysis to the creating of perfectionism profiles: a comparison of two clustering approaches. Front Psychol. 2014;5:1–9. Bolin JH, Edwards JM, Finch WH, Cassady JC. Applications of cluster analysis to the creating of perfectionism profiles: a comparison of two clustering approaches. Front Psychol. 2014;5:1–9.
28.
go back to reference Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–82.PubMedCentralCrossRefPubMed Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–82.PubMedCentralCrossRefPubMed
29.
go back to reference Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.PubMedCentralCrossRefPubMed Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.PubMedCentralCrossRefPubMed
30.
go back to reference Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36:2508–15.PubMedCentralCrossRefPubMed Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36:2508–15.PubMedCentralCrossRefPubMed
31.
go back to reference Ajzen I. The theory of planned behavior. Organizational and Human Decision Processes. 1991;50:179–211.CrossRef Ajzen I. The theory of planned behavior. Organizational and Human Decision Processes. 1991;50:179–211.CrossRef
32.
go back to reference Ware JE. SF-36 v2® Health Questionnaire: Administration Guide for Clinical Trial Investigators. 2008. Ware JE. SF-36 v2® Health Questionnaire: Administration Guide for Clinical Trial Investigators. 2008.
33.
go back to reference Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep. 2002;2:153–9.CrossRefPubMed Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep. 2002;2:153–9.CrossRefPubMed
34.
go back to reference Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–248. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–248.
35.
go back to reference Feldstein AC, Nichols GA, Smith DH, Stevens VJ, Bachman K, Rosales AG, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008;31:1960–5.PubMedCentralCrossRefPubMed Feldstein AC, Nichols GA, Smith DH, Stevens VJ, Bachman K, Rosales AG, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008;31:1960–5.PubMedCentralCrossRefPubMed
36.
go back to reference Feldstein AC, Nichols GA, Smith DH, Rosales AG, Perrin N. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med. 2008;23:1339–45.PubMedCentralCrossRefPubMed Feldstein AC, Nichols GA, Smith DH, Rosales AG, Perrin N. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med. 2008;23:1339–45.PubMedCentralCrossRefPubMed
37.
go back to reference Walraven I, Mast MR, Hoekstra T, Jansen AP, van der Heijden AA, Rauh SP, et al. Distinct HbA1c trajectories in a type 2 diabetes cohort. Acta Diabetol. 2015;52:267–75.CrossRefPubMed Walraven I, Mast MR, Hoekstra T, Jansen AP, van der Heijden AA, Rauh SP, et al. Distinct HbA1c trajectories in a type 2 diabetes cohort. Acta Diabetol. 2015;52:267–75.CrossRefPubMed
Metadata
Title
The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes
Publication date
01-12-2015
Published in
Diabetes Therapy / Issue 4/2015
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-015-0145-8

Other articles of this Issue 4/2015

Diabetes Therapy 4/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.